Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Citation
Wheeler , C M , Skinner , S R , Rowena Del Rosario-Raymundo , M , Garland , S M , Chatterjee , A , Lazcano-Ponce , E , Salmeron , J , McNeil , S , Stapleton , J T , Bouchard , C , Martens , M G , Money , D M , Quek , S C , Romanowski , B , Vallejos , C S , ter Harmsel , B , Prilepskaya , V , Fong , K L , Kitchener , H , Minkina , G , Lim , Y K T , Stoney , T , Chakhtoura , N , Cruickshank , M E , Savicheva , A , da Silva , D P , Ferguson , M , Molijn , A C , Quint , W G V , Hardt , K , Descamps , D , Suryakiran , P V , Karkada , N , Geeraerts , B , Dubin , G , Struyf , F & VIVIANE Study Group 2016 , ' Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study ' , Lancet Infectious Diseases , vol. 16 , no. 10 , pp. 1154-1168 . https://doi.org/10.1016/S1473-3099(16)30120-7